Please login to the form below

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to recruit another 100 patients to add

Latest news

Halozyme halts pancreatic cancer trial

Halozyme halts pancreatic cancer trial. The biopharma company is investigating PEGPH20’ s links to blood clot. ... Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the candidate's safety.
Baxter re-files HyQvia for immunodeficiency in US

HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche wins EU approval for injectable Herceptin

Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Roche's Perjeta backed in EU for breast cancer

Roche is also developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of trastuzumab - partnered with Halozyme Therapeutics - that is also in the latter stages of development.
Roche's T-DM1 activity in breast cancer "outstanding"

Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Pharma deals in June 2015

Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Deal Watch table for December 2014

Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Pharma deals during December 2014

Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Amgen veteran Kurt Gustafson joins Spectrum as CFO

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Consultant Health Economics - London / Oxford: Negotiable

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Project / Account Manager (Medical Education): Salary TBC

Associate Director: £75, 000-90, 000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Medical Writer: Competitive Salary

Director, Market Access / HEOR - North-West: Negotiable

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Associate Medical Director: Highly Competitive

Production Manager – Healthcare Communications: DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: £48, 000 - £60, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director: Excellent benefits

New Business Director - PR: Competitive Salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...